Published in J Exp Med on February 05, 2001
Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol (2001) 7.37
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science (2010) 5.94
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol (2008) 5.17
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med (2006) 4.62
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol (2007) 3.85
Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol (2007) 3.61
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol (2002) 3.38
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med (2004) 2.99
Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol (2006) 2.81
Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol (2008) 2.72
Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response. J Virol (2004) 2.71
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol (2006) 2.70
Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog (2008) 2.59
Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput Biol (2006) 2.48
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
Immune-driven recombination and loss of control after HIV superinfection. J Exp Med (2008) 2.34
A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol (2004) 2.33
Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol (2008) 2.32
Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol (2007) 2.26
Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med (2003) 2.17
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J Virol (2003) 2.15
HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol (2008) 2.14
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A (2005) 2.10
Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol (2004) 2.09
Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J Virol (2004) 2.07
Molecular clocks and the puzzle of RNA virus origins. J Virol (2003) 2.07
De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 2.04
Population dynamics of rapid fixation in cytotoxic T lymphocyte escape mutants of influenza A. Proc Natl Acad Sci U S A (2003) 2.03
The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev (2009) 2.02
Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol (2007) 1.98
HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol (2008) 1.95
A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J Exp Med (2007) 1.88
Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82
Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol (2002) 1.81
Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol (2008) 1.79
Patterns of CD8+ immunodominance may influence the ability of Mamu-B*08-positive macaques to naturally control simian immunodeficiency virus SIVmac239 replication. J Virol (2007) 1.78
Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol (2002) 1.77
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med (2006) 1.72
Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med (2005) 1.69
Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol (2005) 1.67
HLA/KIR restraint of HIV: surviving the fittest. Annu Rev Immunol (2011) 1.66
Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol (2008) 1.66
Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J Virol (2012) 1.62
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther (2013) 1.61
Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther (2009) 1.59
Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J Virol (2003) 1.57
Dynamics of immune escape during HIV/SIV infection. PLoS Comput Biol (2008) 1.54
Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol (2008) 1.53
Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One (2007) 1.52
Frequent toggling between alternative amino acids is driven by selection in HIV-1. PLoS Pathog (2008) 1.49
Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest (2009) 1.46
Reversion in vivo after inoculation of a molecular proviral DNA clone of simian immunodeficiency virus with a cytotoxic-T-lymphocyte escape mutation. J Virol (2005) 1.41
Escape from highly effective public CD8+ T-cell clonotypes by HIV. Blood (2011) 1.39
Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals. Retrovirology (2015) 1.38
Estimating Costs and Benefits of CTL Escape Mutations in SIV/HIV Infection. PLoS Comput Biol (2006) 1.36
Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog (2013) 1.35
Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J Virol (2006) 1.33
Compensatory substitutions restore normal core assembly in simian immunodeficiency virus isolates with Gag epitope cytotoxic T-lymphocyte escape mutations. J Virol (2006) 1.33
Infection with "escaped" virus variants impairs control of simian immunodeficiency virus SIVmac239 replication in Mamu-B*08-positive macaques. J Virol (2009) 1.33
Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One (2007) 1.30
Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences. J Virol (2007) 1.29
Transmission and long-term stability of compensated CD8 escape mutations. J Virol (2008) 1.29
Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol (2012) 1.29
Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 1.29
Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog (2011) 1.27
Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J Virol (2010) 1.26
Immunogenetics of HIV disease. Immunol Rev (2013) 1.25
Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations. PLoS One (2011) 1.24
Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes. J Virol (2005) 1.21
Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol (2003) 1.19
Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J Virol (2010) 1.17
Consequences of cytotoxic T-lymphocyte escape: common escape mutations in simian immunodeficiency virus are poorly recognized in naive hosts. J Virol (2004) 1.17
HLA-B alleles associate consistently with HIV heterosexual transmission, viral load, and progression to AIDS, but not susceptibility to infection. AIDS (2010) 1.17
Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation. J Virol (2005) 1.15
Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol (2010) 1.15
Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B Gag proteins. J Virol (2013) 1.14
HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J Virol (2008) 1.13
HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology (2014) 1.12
Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. Hepatology (2010) 1.11
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science (1995) 18.40
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (1991) 10.85
Estimating effective population size and mutation rate from sequence data using Metropolis-Hastings sampling. Genetics (1995) 10.11
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
The accuracy of reverse transcriptase from HIV-1. Science (1988) 8.24
Fidelity of HIV-1 reverse transcriptase. Science (1988) 8.08
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A (1997) 8.05
MHC ligands and peptide motifs: first listing. Immunogenetics (1995) 7.78
Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell (1996) 6.74
Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens (1995) 6.33
HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature (1988) 5.45
Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science (1996) 5.44
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med (1999) 5.18
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
Identification of self peptides bound to purified HLA-B27. Nature (1991) 4.88
Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med (1995) 4.65
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation. Proc Natl Acad Sci U S A (1993) 4.04
Crystal structure of dimeric HIV-1 capsid protein. Nat Struct Biol (1996) 3.93
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 3.51
Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J Mol Biol (1997) 3.50
Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol (1994) 3.47
The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell (1992) 3.27
Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol (1996) 2.61
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol (1998) 2.50
Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol (1997) 2.32
Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci U S A (1995) 2.30
Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol (1994) 2.18
Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J Biol Chem (1996) 1.94
Model for lentivirus capsid core assembly based on crystal dimers of EIAV p26. J Mol Biol (1999) 1.93
Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS (2000) 1.92
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (1993) 1.56
Sequence constraints and recognition by CTL of an HLA-B27-restricted HIV-1 gag epitope. J Immunol (1995) 1.42
Gag-Gag interactions in the C-terminal domain of human immunodeficiency virus type 1 p24 capsid antigen are essential for Gag particle assembly. J Gen Virol (1996) 1.29
Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry (1997) 1.18
Rational approaches to resistance: using saquinavir. AIDS (1996) 1.13
Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J Med Virol (1995) 1.02
Identification of a novel HLA-B*2705-restricted cytotoxic T-lymphocyte epitope within a conserved region of HIV-1 Nef. AIDS (1997) 0.94
Rational approaches to resistance: nucleoside analogues. AIDS (1996) 0.90
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (1991) 10.85
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science (1995) 10.02
Common west African HLA antigens are associated with protection from severe malaria. Nature (1991) 9.43
Cytotoxic T-cell immunity to influenza. N Engl J Med (1983) 8.49
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol (1993) 8.07
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A (1997) 8.05
Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 7.90
Recombination within natural populations of pathogenic bacteria: short-term empirical estimates and long-term phylogenetic consequences. Proc Natl Acad Sci U S A (2001) 7.90
Bias due to misclassification in the estimation of relative risk. Am J Epidemiol (1977) 7.28
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature (1998) 7.12
Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57
Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol (1993) 6.41
Standardized mortality ratios and the "healthy worker effect": Scratching beneath the surface. J Occup Med (1976) 6.40
Rapid effector function in CD8+ memory T cells. J Exp Med (1997) 6.36
Comparison of HIV-antibody prevalence in patients consenting to and declining HIV-antibody testing in an STD clinic. JAMA (1988) 6.14
Neurological complications of pertussis inoculation. Arch Dis Child (1974) 6.12
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med (2000) 5.79
Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study. N Engl J Med (1992) 5.49
Public health heresy: a challenge to the purchasing orthodoxy. BMJ (1992) 5.45
HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature (1988) 5.45
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33
A human thymocyte antigen defined by a hybrid myeloma monoclonal antibody. Eur J Immunol (1979) 5.17
Molecular cloning, characterization, and complete nucleotide sequence of the gene for pneumolysin, the sulfhydryl-activated toxin of Streptococcus pneumoniae. Infect Immun (1987) 4.92
The epidemic behavior of the hepatitis C virus. Science (2001) 4.81
Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther (1999) 4.65
Potential impact of global climate change on malaria risk. Environ Health Perspect (1995) 4.44
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
The ratio of 2nd to 4th digit length: a predictor of sperm numbers and concentrations of testosterone, luteinizing hormone and oestrogen. Hum Reprod (1998) 4.42
Dependence of chloroplast pigment synthesis on protein synthesis: effect of actidione. Biochem Biophys Res Commun (1965) 4.29
Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol (2004) 4.12
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature (1994) 3.97
Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell (1984) 3.97
Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med (1996) 3.94
Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol (1999) 3.79
Is migraine food allergy? A double-blind controlled trial of oligoantigenic diet treatment. Lancet (1983) 3.79
Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry (2002) 3.78
Evolutionary aspects of recombination in RNA viruses. J Gen Virol (1999) 3.74
Population dynamics of flaviviruses revealed by molecular phylogenies. Proc Natl Acad Sci U S A (1996) 3.69
Excess mortality in England and Wales, and in Greater London, during the 1995 heatwave. J Epidemiol Community Health (1998) 3.67
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2000) 3.66
Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature (1995) 3.61
The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry (2009) 3.59
Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res (1995) 3.59
Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery (1968) 3.56
Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest (1998) 3.53
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother (1992) 3.52
A randomised controlled trial comparing two schedules of antenatal visits: the antenatal care project. BMJ (1996) 3.50
Extinction rates can be estimated from molecular phylogenies. Philos Trans R Soc Lond B Biol Sci (1994) 3.47
The use of a synthetic medium in the isolation of the somatic antigens of Bact. typhi-murium and Bact. typhosum. Biochem J (1940) 3.45
Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med (2001) 3.44
Benign intracranial hypertension following corticosteroid withdrawal in childhood. Br Med J (1970) 3.38
Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol (1992) 3.37
A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol (1999) 3.36
Wildfire responses to abrupt climate change in North America. Proc Natl Acad Sci U S A (2009) 3.34
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med (1999) 3.30
Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol (1997) 3.24
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science (2000) 3.20
Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol (2000) 3.18
Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg (1994) 3.13
A human lymphocyte-associated antigen involved in cell-mediated lympholysis. Eur J Immunol (1983) 3.08
Defying death after DNA damage. Nature (2000) 3.03
Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 3.01
Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med (1996) 2.96
Ecological study of reasons for sharp decline in mortality from ischaemic heart disease in Poland since 1991. BMJ (1998) 2.94
Infection of the surgical site after arthroplasty of the hip. J Bone Joint Surg Br (2005) 2.94
Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. Proc Natl Acad Sci U S A (1991) 2.90
HLA restriction of cell-mediated lysis of influenza virus-infected human cells. Nature (1977) 2.88
Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol (1993) 2.87
Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS (1991) 2.83
Colored noise and computational inference in neurophysiological (fMRI) time series analysis: resampling methods in time and wavelet domains. Hum Brain Mapp (2001) 2.82
Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med (1994) 2.81
Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis (1997) 2.78
Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci U S A (2006) 2.77
A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS (1999) 2.75
Growth in the use of antibiotics in the community in England and Scotland in 1980-93. BMJ (1996) 2.74
High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int Immunol (1990) 2.71
Early effects of climate change: do they include changes in vector-borne disease? Philos Trans R Soc Lond B Biol Sci (2001) 2.71
HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol (2000) 2.69
Clearing the cataract backlog. Br J Ophthalmol (1987) 2.66
Large, identical, tandem repeating units in the C protein alpha antigen gene, bca, of group B streptococci. Proc Natl Acad Sci U S A (1992) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62